Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mitchell

Showing results (1341-1350 of 1,365) with videos related to

Pageof 137
Sort By:
International Journal of Radiation Oncology, Biology, Physics|November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 TrialJay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
JCO Precision Oncology|August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-BPhilippe L Bedard, Shuli Li, Kari B Wisinski, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Alain C Mita, Zihan Wei, et al.
Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
JAMA Network Open|April 5, 2024
Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical TrialMark V Schaverien, Puneet Singh, Benjamin D Smith, et al.
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.
Pageof 137

Showing results (1341-1350 of 1,365) with videos related to

Sort By:
Pageof 137
International Journal of Radiation Oncology, Biology, Physics|November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 TrialJay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
JCO Precision Oncology|August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-BPhilippe L Bedard, Shuli Li, Kari B Wisinski, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Alain C Mita, Zihan Wei, et al.
Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
JAMA Network Open|April 5, 2024
Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical TrialMark V Schaverien, Puneet Singh, Benjamin D Smith, et al.
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.
Pageof 137